Technical Data
BTLA (B and T Lymphocyte Attenuator, CD272)
B and T Lymphocyte Attenuator (BTLA) also known as CD272, is a 70kD type I transmembrane glycoprotein of the CD28 family of T cell costimulatory molecules. BTLA functions as a coinhibitor on activated T cells and on B cells and dendritic cells. The extracellular domain (ECD) of this Ig superfamily protein contains one V-type Ig-like domain, which interacts with the Herpes virus entry mediator (HVEM/TNFSF14). The amino acid sequence of the ECD of human BTLA shares only 34% identity to that of mouse BTLA. One human BTLA variant lacking the transmembrane sequence has been reported.

Suitable for use in Western Blot and Direct ELISA. Other applications not tested.

Recommended Dilutions:
Western Blot: 1-2ug/ml. Using a colormetric detection system, the detection limit is ~5ng/lane under non-reducing and reducing conditions.
Direct ELISA: 0.5-1ug/ml. The detection limit is ~2ng/well.
Optimal dilutions to be determined by the researcher.

Storage and Stability:
Lyophilized powder may be stored at -20C. Stable for 12 months at -20C. Reconstitute with sterile PBS. Aliquot to avoid repeated freezing and thawing. Store at -20C. Reconstituted product is stable for 12 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
MabIgG2a7H92Affinity Purified
100ug-20CBlue IceHumanRat
NS0-derived recombinant human BTLA (aa25-150) UniProt # Q7Z6A9
Purified by Protein G affinity chromatography.
Supplied as a lyophilized powder from PBS, 5% trehalose. Reconstitute with 200ull sterile PBS.
Recognizes human BTLA. Does not crossreact with recombinant mouse BTLA or recombinant human HVEM.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.